GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:SMDPY) » Definitions » Shares Buyback Ratio %

SMDPY (Sumitomo Pharma Co) Shares Buyback Ratio % : 0.00 (As of Dec. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Sumitomo Pharma Co Shares Buyback Ratio %?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Sumitomo Pharma Co's current shares buyback ratio was 0.00%.

Sumitomo Pharma Co Shares Buyback Ratio % Historical Data

The historical data trend for Sumitomo Pharma Co's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sumitomo Pharma Co Shares Buyback Ratio % Chart

Sumitomo Pharma Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sumitomo Pharma Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sumitomo Pharma Co Shares Buyback Ratio % Calculation

Sumitomo Pharma Co's Shares Buyback Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Mar. 2023 ) - Shares Outstanding (EOP) (A: Mar. 2024 )) / Shares Outstanding (EOP) (A: Mar. 2023 )
=(397.292 - 397.291) / 397.292
=0.00%

Sumitomo Pharma Co's Shares Buyback Ratio for the quarter that ended in Sep. 2024 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Jun. 2024 ) - Shares Outstanding (EOP) (A: Sep. 2024 )) / Shares Outstanding (EOP) (A: Jun. 2024 )
=(397.29 - 397.29) / 397.29
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sumitomo Pharma Co Shares Buyback Ratio % Related Terms

Thank you for viewing the detailed overview of Sumitomo Pharma Co's Shares Buyback Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sumitomo Pharma Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:SMDPY) » Definitions » Shares Buyback Ratio %
Comparable Companies
TSE:4540 TSE:4887 TSE:4547 TSE:4521 TSE:4534 TSE:4553 TSE:4569 TSE:4551 TSE:4559 TSE:4886 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 XSWX:SDZ VTRS NBIX
Traded in Other Exchanges
DNPUF:USA 4506:Japan DPM:Germany
Address
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Website
https://www.sumitomo-pharma.com
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.